Literature DB >> 26200835

Rational Manual and Automated Scoring Thresholds for the Immunohistochemical Detection of TP53 Missense Mutations in Human Breast Carcinomas.

Nicholas J Taylor1, Nana Nikolaishvili-Feinberg, Bentley R Midkiff, Kathleen Conway, Robert C Millikan, Joseph Geradts.   

Abstract

Missense mutations in TP53 are common in human breast cancer, have been associated with worse prognosis, and may predict therapy effect. TP53 missense mutations are associated with aberrant accumulation of p53 protein in tumor cell nuclei. Previous studies have used relatively arbitrary cutoffs to characterize breast tumors as positive for p53 staining by immunohistochemical assays. This study aimed to objectively determine optimal thresholds for p53 positivity by manual and automated scoring methods using whole tissue sections from the Carolina Breast Cancer Study. p53-immunostained slides were available for 564 breast tumors previously assayed for TP53 mutations. Average nuclear p53 staining intensity was manually scored as negative, borderline, weak, moderate, or strong and percentage of positive tumor cells was estimated. Automated p53 signal intensity was measured using the Aperio nuclear v9 algorithm combined with the Genie histology pattern recognition tool and tuned to achieve optimal nuclear segmentation. Receiver operating characteristic curve analysis was performed to determine optimal cutoffs for average staining intensity and percent cells positive to distinguish between tumors with and without a missense mutation. Receiver operating characteristic curve analysis demonstrated a threshold of moderate average nuclear staining intensity as a good surrogate for TP53 missense mutations in both manual (area under the curve=0.87) and automated (area under the curve=0.84) scoring systems. Both manual and automated immunohistochemical scoring methods predicted missense mutations in breast carcinomas with high accuracy. Validation of the automated intensity scoring threshold suggests a role for such algorithms in detecting TP53 missense mutations in high throughput studies.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26200835      PMCID: PMC4716889          DOI: 10.1097/PAI.0000000000000207

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  40 in total

1.  Definition of p53 overexpression and its association with the clinicopathological features in luminal/HER2-negative breast cancer.

Authors:  Shoichi Kikuchi; Reiki Nishimura; Tomofumi Osako; Yasuhiro Okumura; Yasuyuki Nishiyama; Yasuo Toyozumi; Nobuyuki Arima
Journal:  Anticancer Res       Date:  2013-09       Impact factor: 2.480

Review 2.  Mutant p53 gain-of-function in cancer.

Authors:  Moshe Oren; Varda Rotter
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-02       Impact factor: 10.005

Review 3.  TP53 mutations in human cancers: origins, consequences, and clinical use.

Authors:  Magali Olivier; Monica Hollstein; Pierre Hainaut
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-01       Impact factor: 10.005

4.  Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis.

Authors:  Anna Yemelyanova; Russell Vang; Malti Kshirsagar; Dan Lu; Morgan A Marks; Ie Ming Shih; Robert J Kurman
Journal:  Mod Pathol       Date:  2011-05-06       Impact factor: 7.842

5.  Prevalence and spectrum of p53 mutations associated with smoking in breast cancer.

Authors:  Kathleen Conway; Sharon N Edmiston; Lisa Cui; S Scott Drouin; Jingzhong Pang; Mei He; Chiu-Kit Tse; Joseph Geradts; Lynn Dressler; Edison T Liu; Robert Millikan; Beth Newman
Journal:  Cancer Res       Date:  2002-04-01       Impact factor: 12.701

Review 6.  Clinical outcomes and correlates of TP53 mutations and cancer.

Authors:  Ana I Robles; Curtis C Harris
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-03       Impact factor: 10.005

7.  p53 status and the efficacy of cancer therapy in vivo.

Authors:  S W Lowe; S Bodis; A McClatchey; L Remington; H E Ruley; D E Fisher; D E Housman; T Jacks
Journal:  Science       Date:  1994-11-04       Impact factor: 47.728

8.  p53 mutations in breast cancer.

Authors:  C Coles; A Condie; U Chetty; C M Steel; H J Evans; J Prosser
Journal:  Cancer Res       Date:  1992-10-01       Impact factor: 12.701

9.  The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry.

Authors:  S Sjögren; M Inganäs; T Norberg; A Lindgren; H Nordgren; L Holmberg; J Bergh
Journal:  J Natl Cancer Inst       Date:  1996-02-21       Impact factor: 13.506

10.  p53 gene mutations inside and outside of exons 5-8: the patterns differ in breast and other cancers.

Authors:  A Hartmann; H Blaszyk; R M McGovern; J J Schroeder; J Cunningham; E M De Vries; J S Kovach; S S Sommer
Journal:  Oncogene       Date:  1995-02-16       Impact factor: 9.867

View more
  5 in total

1.  TP53 protein levels, RNA-based pathway assessment, and race among invasive breast cancer cases.

Authors:  Lindsay A Williams; Ebonee N Butler; Xuezheng Sun; Emma H Allott; Stephanie M Cohen; Ashley M Fuller; Katherine A Hoadley; Charles M Perou; Joseph Geradts; Andrew F Olshan; Melissa A Troester
Journal:  NPJ Breast Cancer       Date:  2018-06-25

2.  Prognostic Significance of RAS Mutations and P53 Expression in Cutaneous Squamous Cell Carcinomas.

Authors:  Manuel António Campos; Sofia Macedo; Margarida Sá Fernandes; Ana Pestana; Joana Pardal; Rui Batista; João Vinagre; Agostinho Sanches; Armando Baptista; José Manuel Lopes; Paula Soares
Journal:  Genes (Basel)       Date:  2020-07-06       Impact factor: 4.096

3.  Non-disruptive mutation in TP53 DNA-binding domain is a beneficial factor of esophageal squamous cell carcinoma.

Authors:  Minran Huang; Jiaoyue Jin; Fanrong Zhang; Yingxue Wu; Chenyang Xu; Lisha Ying; Dan Su
Journal:  Ann Transl Med       Date:  2020-03

4.  Prognostic significance of CD117 expression and TP53 missense mutations in triple-negative breast cancer.

Authors:  Yanli Luo; Wentao Huang; Huizhen Zhang; Guang Liu
Journal:  Oncol Lett       Date:  2018-02-22       Impact factor: 2.967

5.  Genomic profiles of primary and metastatic esophageal adenocarcinoma identified via digital sorting of pure cell populations: results from a case report.

Authors:  Federica Isidori; Deborah Malvi; Silvia Fittipaldi; Claudio Forcato; Isotta Bozzarelli; Claudia Sala; Giovanni Raulli; Antonia D'Errico; Michelangelo Fiorentino; Marco Seri; Kausilia K Krishnadath; Elena Bonora; Sandro Mattioli
Journal:  BMC Cancer       Date:  2018-09-12       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.